WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesPRNewsWire · Oct 9, 2026
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire · Oct 9, 2026
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesPRNewsWire · Oct 8, 2026
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire · Oct 8, 2026
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built AlgorithmBusiness Wire · Oct 8, 2026
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026Business Wire · Oct 6, 2026As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$31.50 | -$9.60 | Beat |
| May 8, 2026 | -$2.40 | -$0.81 | Beat |
| Mar 13, 2026 | -$2.70 | -$1.11 | Beat |
| Nov 14, 2025 | -$2.70 | -$4.74 | Miss |
| Aug 14, 2025 | -$3.00 | -$5.10 | Miss |
| May 15, 2025 | -$4.80 | -$4.80 | Beat |